Goldman Sachs Sell-side卖方

Novo Nordisk (NOVOb.CO) Wegovy pill remains the key short term driver, but longer term LOE risk will continue to weigh

Aug 6, 202615 pages页

From the report报告摘录ZEUS/REIMAGINE-4 failure dominates pipeline risk: Phase 3 trial failures for ziltivekimab (ZEUS) and semaglutide (REIMAGINE-4) trigger removal of ziltivekimab sales forecasts and moderate CagriSema peak sales estimates…

Read the full report + PDF阅读全文与 PDF

The full summary (5 key points) and the original Goldman Sachs PDF are for MastermindX Pro members. 完整摘要（5 个要点）与 Goldman Sachs 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →